Key facts
- This page summarizes Todd Shegog's Form 4 filing for Cogent Biosciences, Inc. (COGT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Jun 2025, 16:21.
Todd Shegog - 04 Jun 2025 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)
- Reporting relationship
- Director
- Issuer ticker
- COGT
- Reported as of
- 04 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2025, 16:21:25 UTC
- Prior SEC filing
- 13 Jun 2024
- Next SEC filing
- 11 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Evan D. Kearns, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Todd Shegog filed Form 4 for Cogent Biosciences, Inc. (COGT) on 05 Jun 2025.
Change
- Previous filing in this sequence was filed on 13 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001714564
Primary reporting owner
Shegog Todd
- Relationship
- Director
- Address
- C/O COGENT BIOSCIENCES, INC., 275 WYMAN STREET, 3RD FLOOR, WALTHAM
- Signature
- /s/ Evan D. Kearns, Attorney-in-Fact
- Signature date
- 05 Jun 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
COGT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +44,700
- Change %
- Price
- $0.000000
- Shares after
- 44,700
- Date
- 04 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 44,700
- Exercise price
- $5.64
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders.